225 related articles for article (PubMed ID: 26859076)
1. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.
Miranda MB; Lauseker M; Kraus MP; Proetel U; Hanfstein B; Fabarius A; Baerlocher GM; Heim D; Hossfeld DK; Kolb HJ; Krause SW; Nerl C; Brümmendorf TH; Verbeek W; Fauser AA; Prümmer O; Neben K; Hess U; Mahlberg R; Plöger C; Flasshove M; Rendenbach B; Hofmann WK; Müller MC; Pfirrmann M; Hochhaus A; Hasford J; Hehlmann R; Saußele S
Leukemia; 2016 Jun; 30(6):1255-62. PubMed ID: 26859076
[TBL] [Abstract][Full Text] [Related]
2. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.
Nakazato T; Iriyama N; Tokuhira M; Ishikawa M; Sato E; Takaku T; Sugimoto KJ; Fujita H; Fujioka I; Kimura Y; Aisa Y; Iwanaga E; Asou N; Kizaki M; Hatta Y; Komatsu N; Kawaguchi T
Med Oncol; 2018 May; 35(7):99. PubMed ID: 29846829
[TBL] [Abstract][Full Text] [Related]
3. Hodgkin Lymphoma in a Case of Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors.
Gajendra S; Sharma A; Sharma R; Gupta SK; Sood N; Sachdev R
Turk Patoloji Derg; 2019; 35(1):74-78. PubMed ID: 28272671
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors.
Yin XF; Wang JH; Li X; Yu MX; Ma ZX; Jin J
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):577-581. PubMed ID: 27397576
[TBL] [Abstract][Full Text] [Related]
5. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.
Koller PB; Kantarjian HM; Nogueras-Gonzalez GM; Jabbour E; Verstovsek S; Borthakur G; Estrov Z; Wierda WG; Garcia-Manero G; Ferrajoli A; Ravandi F; O'Brien SM; Cortes JE
Cancer; 2017 Feb; 123(4):609-616. PubMed ID: 27763690
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
7. Secondary malignancy after imatinib therapy: eight cases and review of the literature.
Duman BB; Paydas S; Disel U; Besen A; Gurkan E
Leuk Lymphoma; 2012 Sep; 53(9):1706-8. PubMed ID: 22329351
[TBL] [Abstract][Full Text] [Related]
8. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.
Gunnarsson N; Stenke L; Höglund M; Sandin F; Björkholm M; Dreimane A; Lambe M; Markevärn B; Olsson-Strömberg U; Richter J; Wadenvik H; Wallvik J; Själander A
Br J Haematol; 2015 Jun; 169(5):683-8. PubMed ID: 25817799
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
10. Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia.
Voglova J; Muzik J; Faber E; Zackova D; Klamova H; Steinerova K; Michalovicova Z; Demitrovicova L; Cmunt E; Novakova L; Tothova E; Belohlavkova P; Mayer J; Indrak K
Neoplasma; 2011; 58(3):256-62. PubMed ID: 21395367
[TBL] [Abstract][Full Text] [Related]
11. Non-Hodgkin's lymphoma developed during imatinib mesylate treatment of chronic myeloid leukemia.
Kassar O; Kahla AB; Koubaa A; Kallel F; Amor IB; Elloumi M
J Oncol Pharm Pract; 2023 Jun; 29(4):996-998. PubMed ID: 36344191
[TBL] [Abstract][Full Text] [Related]
12. Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia.
Gugliotta G; Castagnetti F; Breccia M; Albano F; Iurlo A; Intermesoli T; Abruzzese E; Levato L; D'Adda M; Pregno P; Cavazzini F; Stagno F; Martino B; La Barba G; Sorà F; Tiribelli M; Bigazzi C; Binotto G; Bonifacio M; Caracciolo C; Soverini S; Foà R; Cavo M; Martinelli G; Pane F; Saglio G; Baccarani M; Rosti G;
Haematologica; 2017 Sep; 102(9):1530-1536. PubMed ID: 28572163
[TBL] [Abstract][Full Text] [Related]
13. A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.
Castagnetti F; Di Raimondo F; De Vivo A; Spitaleri A; Gugliotta G; Fabbiano F; Capodanno I; Mannina D; Salvucci M; Antolino A; Marasca R; Musso M; Crugnola M; Impera S; Trabacchi E; Musolino C; Cavazzini F; Mineo G; Tosi P; Tomaselli C; Rizzo M; Siragusa S; Fogli M; Ragionieri R; Zironi A; Soverini S; Martinelli G; Cavo M; Vigneri P; Stagno F; Rosti G; Baccarani M
Am J Hematol; 2017 Jan; 92(1):82-87. PubMed ID: 27770583
[TBL] [Abstract][Full Text] [Related]
14. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study.
Rebora P; Czene K; Antolini L; Gambacorti Passerini C; Reilly M; Valsecchi MG
Am J Epidemiol; 2010 Nov; 172(9):1028-33. PubMed ID: 20861143
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
[TBL] [Abstract][Full Text] [Related]
16. Newly diagnosed breast cancer in a patient receiving imatinib mesylate.
Kaygusuz-Atagunduz I; Toptas T; Yumuk F; Firatli-Tuglular T; Bayik M
J Cancer Res Ther; 2014; 10(4):1107-8. PubMed ID: 25579564
[TBL] [Abstract][Full Text] [Related]
17. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F; Gugliotta G; Breccia M; Stagno F; Iurlo A; Albano F; Abruzzese E; Martino B; Levato L; Intermesoli T; Pregno P; Rossi G; Gherlinzoni F; Leoni P; Cavazzini F; Venturi C; Soverini S; Testoni N; Alimena G; Cavo M; Martinelli G; Pane F; Saglio G; Rosti G; Baccarani M;
Leukemia; 2015 Sep; 29(9):1823-31. PubMed ID: 26088952
[TBL] [Abstract][Full Text] [Related]
19. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.
Verma D; Kantarjian H; Strom SS; Rios MB; Jabbour E; Quintas-Cardama A; Verstovsek S; Ravandi F; O'Brien S; Cortes J
Blood; 2011 Oct; 118(16):4353-8. PubMed ID: 21846902
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.
Kalmanti L; Saussele S; Lauseker M; Müller MC; Dietz CT; Heinrich L; Hanfstein B; Proetel U; Fabarius A; Krause SW; Rinaldetti S; Dengler J; Falge C; Oppliger-Leibundgut E; Burchert A; Neubauer A; Kanz L; Stegelmann F; Pfreundschuh M; Spiekermann K; Scheid C; Pfirrmann M; Hochhaus A; Hasford J; Hehlmann R
Leukemia; 2015 May; 29(5):1123-32. PubMed ID: 25676422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
